# US 2021/0171553 A1 · Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171553 A1
- Document ID: US20210171553A1
- Status: Published application
- Kind: A1
- Application number: 17/140,789
- Filed: 2021-01-04
- Published: 2021-06-10
- Earliest claimed: 2017-02-23
- Assignees: The University of Toledo; Washington State University
- Applicants: The University of Toledo; Washington State University
- Inventors: Kenneth Hensley; Travis Denton
- Web page: https://patentgrep.com/patent/US20210171553A1

## CPC

- C07F 9/6544: Six-membered rings
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Lanthionine ketimine phosphonate (LK-P), lanthionine ketimine ester phosphonate (LKE-P), other lanthionine ketimine, lanthionine ketimine phosphonate, and lanthionine ketimine ester derivatives, methods of making and using the same, and methods of treatments are described.

## Claims

### Claim 1

A compound comprising Formula F:
wherein:
R1 is H or substituted or unsubstituted alkyl, aryl, alkoxy, ester, alkenylamino, alkynylamino, aryloxy, aralkoxy, acyloxy, alkylamino, arylamino, aralkylamino, or amido;
R2 is selected from the group consisting of COOH, COOR4, PO(OH)2, PO(OR4)2, POOR4OR5, and POOR4OX, wherein R4 and R5 are each independently alkyl groups, and X is hydrogen, a group I metal, a halide, or substituted or unsubstituted alkyl, alkoxy, ester, alkenylamino, alkynylamino, aryloxy, aralkoxy, acyloxy, alkylamino, arylamino, aralkylamino, or amido;
R3 is H or a substituted or unsubstituted alkyl, alkoxy, ester, alkenylamino, alkynylamino, aryloxy, aralkoxy, acyloxy, alkylamino, arylamino, aralkylamino, or amido;
excluding when R1 is H and R2 is COOH, R3 is not ethyl or H; and,
excluding when R1 is H, R2 is COOR where R1 is unsubstituted alkyl (ethyl), and R3 is susubstituted ethyl,
and salts, stereoisomers, racemates, hydrates, solvates, polymorphs, and alkene reduction products thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R2 is COOH or COOR4.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R2 is COOH or COOR4, and R3 is alkyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is alkyl.

### Claim 5 (depends on 1)

The compound of claim 1, comprising a substituent to facilitate transport of the compound through the blood brain barrier.

### Claim 6 (depends on 1)

A compound of claim 1, comprising 2-n-hexyl-LKE-P having Formula XIV:
and salts, stereoisomers, racemates, hydrates, solvates, polymorphs, and alkene reduction products thereof.

### Claim 7 (depends on 1)

A compound of claim 1, comprising 2-isopropyl lanthionine ketimine ethyl ester phosphonate (2-isopropyl-LKE-P) having Formula X
and salts, stereoisomers, racemates, hydrates, solvates, polymorphs, and alkene reduction products thereof.

### Claim 8 (depends on 1)

A pharmaceutical composition comprising:
a therapeutically effective amount of a compound of claim 1; and
a pharmaceutically acceptable carrier, diluent, or adjuvant.

### Claim 9 (depends on 1)

A method of reducing replicative capacity of cells, the method comprising administering an effective amount of a compound of claim 1, to cells, and reducing replicative capacity of the cells.

### Claim 10 (depends on 1)

A method of treating an autophagy-related disease, the method comprising administering an effective amount of a compound of claim 1, to a subject in need thereof and treating an autophagy-related disease.

### Claim 11 (depends on 10)

The method of claim 10, wherein the autophagy-related disease is amyotrophic lateral sclerosis (ALS).

### Claim 12 (depends on 10)

The method of claim 10, wherein the autophagy-related disease is Parkinson's disease.

### Claim 13 (depends on 10)

The method of claim 10, wherein the subject is a human subject.

### Claim 14 (depends on 1)

A method of reducing damage to a cell resulting from oxidative stress, excitotoxicity, free radical toxicity, or excitatory amino acid toxicity, the method comprising contacting a cell with a compound of claim 1 and reducing damage to the cell, wherein the cell is a neuron, macrophage, or glial cell.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cell is selected from the group consisting of astrocytes, microglia, oligodendrocytes, and ependyma.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cell is present in a human subject.

### Claim 17 (depends on 1)

A method of treating a patient having an inflammatory disease, the method comprising administering a therapeutically effective amount of a compound of claim 1, to a patient having an inflammatory disease to treat the patient.

### Claim 18 (depends on 17)

The method of claim 17, wherein the inflammatory disease is rheumatoid arthritis or inflammatory bowel disease.

### Claim 19 (depends on 1)

A method of treating a patient having a neurodegenerative disease, the method comprising administering a therapeutically effective amount of a compound of claim 1, to a patient having a neurodegenerative disease to treat the patient.

### Claim 20 (depends on 19)

The method of claim 19, wherein the neurodegenerative disease is selected from one of: Parkinson's disease, multiple sclerosis, or amyotrophic lateral sclerosis.
